BCR-ABL gene fusion, with constitutive tyrosine kinase activity, has been found in almost 90% of CML cases and is consistently related to cell morphology, clinical manifestation, and laboratory parameters [38]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.